We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Johnson & Johnson, NextEra, Deere, Cintas and Canadian Pacific
Read MoreHide Full Article
For Immediate Release
Chicago, IL – July 19, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Johnson & Johnson (JNJ - Free Report) , NextEra (NEE - Free Report) , Deere (DE - Free Report) , Cintas (CTAS - Free Report) and Canadian Pacific (CP - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Stock Reports for J&J, NextEra and Deere
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ - Free Report) , NextEra (NEE - Free Report) and Deere (DE - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Johnson & Johnson's shares have outperformed the Zacks Large Cap Pharmaceuticals industry so far this year (+2.2% vs. -1.2%). J&J beat estimates for earnings and sales in Q2 and raised the 2019 guidance for operational sales growth for the second time this year.
The Zacks analyst thinks J&J is witnessing significant generic/biosimilar headwinds in its Pharma unit in 2019. However, J&J’s sales and earnings growth is expected to accelerate in 2020 supported by contribution from new drugs like Tremfya and successful label expansion of cancer drugs like Imbruvica and Darzalex and immunology drug, Stelara.
J&J is also making rapid progress with its pipeline and line extensions. It has already gained FDA approval for two new drugs in 2019, Balversa and Spravato. Headwinds like biosimilar/generic competition and pricing pressure remain. The talc and opioid litigations are overhangs on the stock.
Shares of NextEra have outperformed the Zacks Electric Power industry in the past year, gaining +23.3% vs +11.8%. The Zacks analyst thinks NextEra’s investments to strengthen renewable operations through “30 by 30” plan will help the company to continue as a market leader in renewable power generation. Focus on expanding operations in natural gas pipelines and further expansion of business through acquisitions and organic growth have positively impacted earnings.
However, its nature of business is subject to complex and comprehensive federal, state, and other regulations. Substantial investments are undertaken to ensure the safety of nuclear operations. If planned outages last longer than expected, or there is an unplanned outage normal operations and profitability might be hindered.
Deere’s shares have gained +16.2% in the past year, underperforming the Zacks Farm Equipment industry, which has increased +14.3% over the same period. For fiscal 2019, Deere expects net sales to increase 5% year over year. Concerns stemming from the U.S-China trade war and lower commodity prices have led to farmers getting cautious about their equipment purchases.
However, the Zacks analyst thinks the $16 billion aid program for American farmers impacted by the trade war is likely to bolster agricultural equipment sales, which bodes well for Deere. Improving construction markets and the Wirtgen acquisition, which has increased Deere's exposure to global transportation infrastructure, will benefit results.
Additionally, introduction of advanced technologies in its products will aid growth. However, raw material cost inflation, elevated expenses and unfavorable foreign currency impact remain near-term headwinds.
Other noteworthy reports we are featuring today include Cintas and Canadian Pacific.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Johnson & Johnson, NextEra, Deere, Cintas and Canadian Pacific
For Immediate Release
Chicago, IL – July 19, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Johnson & Johnson (JNJ - Free Report) , NextEra (NEE - Free Report) , Deere (DE - Free Report) , Cintas (CTAS - Free Report) and Canadian Pacific (CP - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Stock Reports for J&J, NextEra and Deere
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ - Free Report) , NextEra (NEE - Free Report) and Deere (DE - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Johnson & Johnson's shares have outperformed the Zacks Large Cap Pharmaceuticals industry so far this year (+2.2% vs. -1.2%). J&J beat estimates for earnings and sales in Q2 and raised the 2019 guidance for operational sales growth for the second time this year.
The Zacks analyst thinks J&J is witnessing significant generic/biosimilar headwinds in its Pharma unit in 2019. However, J&J’s sales and earnings growth is expected to accelerate in 2020 supported by contribution from new drugs like Tremfya and successful label expansion of cancer drugs like Imbruvica and Darzalex and immunology drug, Stelara.
J&J is also making rapid progress with its pipeline and line extensions. It has already gained FDA approval for two new drugs in 2019, Balversa and Spravato. Headwinds like biosimilar/generic competition and pricing pressure remain. The talc and opioid litigations are overhangs on the stock.
Shares of NextEra have outperformed the Zacks Electric Power industry in the past year, gaining +23.3% vs +11.8%. The Zacks analyst thinks NextEra’s investments to strengthen renewable operations through “30 by 30” plan will help the company to continue as a market leader in renewable power generation. Focus on expanding operations in natural gas pipelines and further expansion of business through acquisitions and organic growth have positively impacted earnings.
However, its nature of business is subject to complex and comprehensive federal, state, and other regulations. Substantial investments are undertaken to ensure the safety of nuclear operations. If planned outages last longer than expected, or there is an unplanned outage normal operations and profitability might be hindered.
Deere’s shares have gained +16.2% in the past year, underperforming the Zacks Farm Equipment industry, which has increased +14.3% over the same period. For fiscal 2019, Deere expects net sales to increase 5% year over year. Concerns stemming from the U.S-China trade war and lower commodity prices have led to farmers getting cautious about their equipment purchases.
However, the Zacks analyst thinks the $16 billion aid program for American farmers impacted by the trade war is likely to bolster agricultural equipment sales, which bodes well for Deere. Improving construction markets and the Wirtgen acquisition, which has increased Deere's exposure to global transportation infrastructure, will benefit results.
Additionally, introduction of advanced technologies in its products will aid growth. However, raw material cost inflation, elevated expenses and unfavorable foreign currency impact remain near-term headwinds.
Other noteworthy reports we are featuring today include Cintas and Canadian Pacific.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.